Items Tagged ‘zelboraf’

October 7th, 2015

Zelboraf® Appears Active in Hairy Cell Leukemia That Has Progressed After Other Treatment

By

The medication Zelboraf® (vemurafenib) appears active in the treatment of hairy cell leukemia (HCL) that had progressed after previous therapy. These findings were published in New England Journal of Medicine. Hairy cell leukemia is a rare type of leukemia, or cancer of the immune cells. In HCL, the bone marrow makes too many lymphocytes (a […]

View full entry

Tags: BRAF, Hairy Cell Leukemia, HCL, Leukemia, News, vemurafenib, zelboraf


September 24th, 2015

Zelboraf® Active in Hairy Cell Leukemia

By

The targeted agent, Zelboraf® (vemurafenib), which is approved for the treatment of melanoma, provided high anti-cancer activity among patients with hairy-cell leukemia that had stopped responding to prior therapies. These results were recently published in the New England Journal of Medicine. Hairy-cell leukemia is a type of cancer in which too many abnormal immune cells […]

View full entry

Tags: BRAF V600E mutation, Hairy Cell Leukemia, Leukemia, News, vemurafenib, zelboraf


October 8th, 2014

COMBI-v BRAF/MEK Inhibitor Combination Trial Impressive in Melanoma

By

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology Meeting this week. Of the more than one million new diagnoses of skin cancer each year, roughly 68,000 involve melanoma. More than 8,000 people die of melanoma each […]

View full entry

Tags: Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, tafinalr, trametinib, zelboraf


October 2nd, 2014

BRAF/MEK Inhibitor Combination Impressive in Melanoma Trials

By

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology Meeting this week. Of the more than one million new diagnoses of skin cancer each year, roughly 68,000 involve melanoma. More than 8,000 people die of melanoma each […]

View full entry

Tags: BRAF, cobimetinib, cobrim, mek, Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, vemurafenib, zelboraf


July 25th, 2014

Study of Combination Therapy in Cutaneous Melanoma Stopped Early to Allow Crossover

By

An Independent Data Monitoring Committee recently recommended that a clinical study of the combination treatment Mekinist™ (trametinib) plus Tafinlar™ (dabrafenib) versus Zelboraf® (vemurafenib) for metastatic cutaneous melanoma patients be stopped early so that those receiving Zelboraf could cross over and begin taking the combination therapy instead. The committee made the recommendation after an interim analysis […]

View full entry

Tags: mekinist, Melanoma, News, Stage III Melanoma, Stage IV Melanoma, tafinlar, zelboraf